HCR Wealth Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

HCR Wealth Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,011	Closed	-$11K	–	181
2022 Q2	$11K	Buy	+10,011	New	+$16.5K	﹤0.01%	177

Other funds holding EVFM

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

HCR Wealth Advisors's EVFM Position: Q3 2022 in Review

HCR Wealth Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 10,011 shares — an estimated $11K sold.

HCR Wealth Advisors first reported a position in EVFM in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

HCR Wealth Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
HCR Wealth Advisors sold 10,011 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $11K.
HCR Wealth Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
HCR Wealth Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $11K in Q2 2022.
8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on HCR Wealth Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.